Part 2 – Case Discussion

Erin Schenk, MD, PhD, and D. Ross Camidge, MD, PhD, medical oncologists at the University of Colorado Cancer Center, discuss treatment options, including consolidation therapy, for a 53-year-old woman with advanced stage IIIC NSCLC. Guidelines and clinical trial data did not include information specific to the patient’s disease stage; therefore, Drs Schenk and Camidge discuss the considerations for treatment and the shared decision-making process.

Visit this link to continue to Part 3 – Case Discussion & Wrap-up.

Disclosures:

Erin Schenk, MD, PhD
Consulting Fees: Guidepoint, Physicians’ Education Resource

D. Ross Camidge, MD, PhD
Consulting Fees: Amgen, Anchiarno, Apollomics, AstraZeneca, Bio-Thera, BMS, Daiichi-Sankyo, Eisai, Elevation, Eli Lilly, EMD Serono, GSK, Helssin, Janssen, Nuvalent, Onkure, Mersana, Pfizer, Qilu, Roche, Sanofi, Seattle Genetics, Takeda
Contracted Research: AbbVie, AstraZeneca, BMS, GSK, Hansoh, Inhibrx, Inivata, Karyopharm, Lycera, Medimmune, Merck, Pfizer, Phosplatin, Psioxus, Rain, Roche/Genentech, Seattle Genetics, Symphogen, Takeda, Tolero